Tech Company Financing Transactions
Perlegen Sciences Funding Round
Perlegen Sciences closed a $74 million Series D funding round on 2/28/2005. Investors included Bain Capital Ventures, MPM Capital and Presidio Partners.
Transaction Overview
Company Name
Announced On
2/28/2005
Transaction Type
Venture Equity
Amount
$74,000,000
Round
Series D
Investors
Proceeds Purpose
This equity financing will enable us to continue in-licensing and developing a valuable pipeline of late-stage drugs, exploiting Perlegen's ability to target the right drugs to the right patients.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
2021 Stierlin Court
Mountain View, CA 94043
USA
Mountain View, CA 94043
USA
Phone
Website
Email Address
Overview
Perlegen Sciences, Inc. is working to provide safe and effective medicines to patients worldwide. The company quickly and cost effectively analyzes millions of unique genetic variations in clinical trial participants to develop genetically targeted, late stage therapeutics and diagnostics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bryan Walser
Chief Financial Officer
Joseph Lehnen
VP - Bus. Development
Kevin Cooksy
VP - Finance
Christopher Pascoe
VP - Human Resources
Brenda Rogers
VP - Operations
Brian Rhees
VP - Sales
Mark Ostrowski
Browse more venture capital transactions:
Prev: 2/28/2005: Active Reasoning venture capital transaction
Next: 2/28/2005: CLK Design Automation venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs